Risk factors
Ernexa Therapeutics (ERNA) risk factors
Item 1A of every Ernexa Therapeutics Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors34 risks2 dropped3 reworded
The company addressed Nasdaq continued listing requirements after receiving a deficiency notice, noting equity dropped to approximately $2.4 million before a $9.5 million public offering.
Filed Mar 13, 2026 - FY2024 10-K risk factors36 risks
Capital requirements and ongoing operating losses dominate the risk profile alongside strong reliance on in-licensed technology from Factor Limited.
Filed Mar 12, 2025